Metagenomi, Inc. Common Stock - Asset Resilience Ratio
Metagenomi, Inc. Common Stock (MGX) has an Asset Resilience Ratio of 47.00% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Metagenomi, Inc. Common Stock current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how Metagenomi, Inc. Common Stock's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Metagenomi, Inc. Common Stock asset portfolio.
Liquid Assets Composition Over Time
This chart breaks down Metagenomi, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Metagenomi, Inc. Common Stock strategic investment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $81.64 Million | 47.0% |
| Total Liquid Assets | $81.64 Million | 47.00% |
Asset Resilience Insights
- Very High Liquidity: Metagenomi, Inc. Common Stock maintains exceptional liquid asset reserves at 47.00% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Metagenomi, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Metagenomi, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Metagenomi, Inc. Common Stock (2021–2025)
The table below shows the annual Asset Resilience Ratio data for Metagenomi, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-09-30 | 53.86% | $119.08 Million | $221.10 Million | -14.20pp |
| 2024-09-30 | 68.06% | $220.92 Million | $324.60 Million | +32.27pp |
| 2023-09-30 | 35.79% | $130.58 Million | $364.84 Million | -7.08pp |
| 2022-09-30 | 42.87% | $177.69 Million | $414.49 Million | -5.62pp |
| 2021-09-30 | 48.49% | $68.86 Million | $141.99 Million | -- |
About Metagenomi, Inc. Common Stock
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for … Read more